These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33136151)

  • 1. Early-Life Body Adiposity and the Breast Tumor Transcriptome.
    Wang J; Peng C; Guranich C; Heng YJ; Baker GM; Rubadue CA; Glass K; Eliassen AH; Tamimi RM; Polyak K; Hankinson S
    J Natl Cancer Inst; 2021 Jun; 113(6):778-784. PubMed ID: 33136151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alcohol consumption and breast tumor gene expression.
    Wang J; Heng YJ; Eliassen AH; Tamimi RM; Hazra A; Carey VJ; Ambrosone CB; de Andrade VP; Brufsky A; Couch FJ; King TA; Modugno F; Vachon CM; Hunter DJ; Beck AH; Hankinson SE
    Breast Cancer Res; 2017 Sep; 19(1):108. PubMed ID: 28899409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of early menarche with breast tumor molecular features and recurrence.
    Harris AR; Wang T; Heng YJ; Baker GM; Le PA; Wang J; Ambrosone C; Brufsky A; Couch FJ; Modugno F; Scott CG; Vachon CM; Hankinson SE; Rosner BA; Tamimi RM; Peng C; Eliassen AH
    Breast Cancer Res; 2024 Jun; 26(1):102. PubMed ID: 38886818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues.
    Heng YJ; Wang J; Ahearn TU; Brown SB; Zhang X; Ambrosone CB; de Andrade VP; Brufsky AM; Couch FJ; King TA; Modugno F; Vachon CM; DuPre NC; Garcia-Closas M; Troester MA; Hunter DJ; Eliassen AH; Tamimi RM; Hankinson SE; Beck AH
    Breast Cancer Res Treat; 2019 Feb; 173(3):667-677. PubMed ID: 30387004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose environmental radon exposure and breast tumor gene expression.
    Peng C; DuPre N; VoPham T; Heng YJ; Baker GM; Rubadue CA; Glass K; Sonawane A; Zeleznik O; Kraft P; Hankinson SE; Eliassen AH; Hart JE; Laden F; Tamimi RM
    BMC Cancer; 2020 Jul; 20(1):695. PubMed ID: 32723380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the adolescent female breast transcriptome and the impact of obesity.
    Burkholder A; Akrobetu D; Pandiri AR; Ton K; Kim S; Labow BI; Nuzzi LC; Firriolo JM; Schneider SS; Fenton SE; Shaw ND
    Breast Cancer Res; 2020 May; 22(1):44. PubMed ID: 32393308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer.
    Fuentes-Mattei E; Velazquez-Torres G; Phan L; Zhang F; Chou PC; Shin JH; Choi HH; Chen JS; Zhao R; Chen J; Gully C; Carlock C; Qi Y; Zhang Y; Wu Y; Esteva FJ; Luo Y; McKeehan WL; Ensor J; Hortobagyi GN; Pusztai L; Fraser Symmans W; Lee MH; Yeung SC
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24957076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body size in early life and risk of breast cancer.
    Shawon MSR; Eriksson M; Li J
    Breast Cancer Res; 2017 Jul; 19(1):84. PubMed ID: 28732505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
    Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
    Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altersolanol B, a fungal tetrahydroanthraquinone, inhibits the proliferation of estrogen receptor-expressing (ER+) human breast adenocarcinoma by modulating PI3K/AKT, p38/ERK MAPK and associated signaling pathways.
    Siraj MA; Jacobs AT; Tan GT
    Chem Biol Interact; 2022 May; 359():109916. PubMed ID: 35346647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
    Ciruelos Gil EM
    Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
    Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parity-related molecular signatures and breast cancer subtypes by estrogen receptor status.
    Rotunno M; Sun X; Figueroa J; Sherman ME; Garcia-Closas M; Meltzer P; Williams T; Schneider SS; Jerry DJ; Yang XR; Troester MA
    Breast Cancer Res; 2014 Jul; 16(4):R74. PubMed ID: 25005139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival.
    Pande M; Bondy ML; Do KA; Sahin AA; Ying J; Mills GB; Thompson PA; Brewster AM
    Breast Cancer Res Treat; 2014 Sep; 147(2):381-7. PubMed ID: 25108739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSNK1G2 differently sensitizes tamoxifen-induced decrease in PI3K/AKT/mTOR/S6K and ERK signaling according to the estrogen receptor existence in breast cancer cells.
    Nguyen Hoang AT; Hoe KL; Lee SJ
    PLoS One; 2021; 16(4):e0246264. PubMed ID: 33861751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of fine particulate matter exposure with gene expression pathways in breast tumor and adjacent-normal breast tissue.
    DuPré NC; Heng YJ; Raby BA; Glass K; Hart JE; Chu JH; Askew C; Eliassen AH; Hankinson SE; Kraft P; Laden F; Tamimi RM
    Environ Res; 2020 Jul; 186():109535. PubMed ID: 32668536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
    Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
    Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
    Araki K; Miyoshi Y
    Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers.
    Manzano RG; Martinez-Navarro EM; Forteza J; Brugarolas A
    Int J Oncol; 2014 Dec; 45(6):2250-66. PubMed ID: 25201346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.